Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parke-Davis/Ribozyme Pharmaceuticals agreement

Executive Summary

Collaboration announced April 21 will apply RPI's ribozyme technology to the treatment of osteoarthritis. The deal includes an equity investment in RPI by the Warner-Lambert division, as well as royalties and milestone payments to RPI. RPI will manufacture and the two companies will copromote in North America any products developed through the agreement. Boulder, Colo.-based RPI is currently developing ribozymes for HIV, herpes simplex virus and cardiovascular restenosis.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel